Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés.
View in English
Respuesta de Siontis et al a la carta relativa al artículo "Resultados asociados con el uso de apixaban en pacientes con enfermedad renal terminal y fibrilación auricular en los Estados Unidos"
- Konstantinos C Siontis 1, Xiaosong Zhang 2, Douglas E Schaubel 3, Xiaoxi Yao 4,5, Peter A Noseworthy 1,4, Nilay D Shah 4,5, Rajiv Saran 2,6, Brahmajee K Nallamothu 7,8
- 1Department of Cardiovascular Medicine (K.C.S., P.A.N.), Mayo Clinic, Rochester, MN.
- 2Department of Internal Medicine (X.Z., R.S.), University of Michigan, Ann Arbor.
- 3Department of Biostatistics, School of Public Health (D.E.S.), University of Michigan, Ann Arbor.
- 4Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (X.Y., P.A.N., N.D.S.), Mayo Clinic, Rochester, MN.
- 5Department of Health Sciences Research, Division of Health Care Policy and Research (X.Y., N.D.S.), Mayo Clinic, Rochester, MN.
- 6Kidney Epidemiology and Cost Center, School of Public Health (R.S.), University of Michigan, Ann Arbor.
- 7Institute for Healthcare Policy and Innovation (B.K.N.), University of Michigan, Ann Arbor.
- 8Division of Cardiovascular Medicine, Department of Internal Medicine (B.K.N.), University of Michigan, Ann Arbor.
- 0Department of Cardiovascular Medicine (K.C.S., P.A.N.), Mayo Clinic, Rochester, MN.
Videos de Experimentos Relacionados
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Videos de Experimentos Relacionados
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.